Indeed, ovarian tumors with BRCA1 or BRCA2 mutations, either germline or somatic, are associated with higher mutational burden and better survival outcomes following treatment with platinum-based chemotherapy [53] or PARP inhibitors [54]. Here, BRCA2 is linked to ovarian neoplasm.